Akari Therapeutics (AKTX)

• Market cap: $6.87M
• 1 day: 3.63%
• 5 days: 16.5%
• 1 month: 3.45%
• 3 months: -45.16%
• 6 months: -79.7%
• Year to date: -48.28%
• 1 year: -89.66%
• 5 years: -99.68%
• 10 years: -99.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Employees: 5